Alterity’s ATH434 Demonstrates Functional Benefits in MSA with New Composite Scale
Alterity Therapeutics has unveiled fresh Phase 2 data revealing ATH434’s ability to slow functional decline in Multiple System Atrophy patients, measured by the novel MuSyCA scale. This reinforces the drug’s disease-modifying potential ahead of pivotal Phase 3 trials.
- ATH434 slowed disease progression on MuSyCA composite scale at 52 weeks
- Treatment effect ranged from −1.9 to −4.0 points versus placebo
- MuSyCA integrates patient function and neurological exam for sensitivity
- Data support regulatory engagement for Phase 3 pivotal trial
- ATH434 holds Fast Track and Orphan Drug designations for MSA
New Composite Scale Highlights ATH434’s Clinical Impact
Alterity Therapeutics (ASX:ATH) has presented a compelling new analysis from its Phase 2 trial of ATH434 in Multiple System Atrophy (MSA), showing the drug slows functional decline when assessed with the novel MuSyCA composite scale. Delivered during a Late Breaking Science session at the American Academy of Neurology annual meeting in Chicago, the data reveal ATH434’s ability to reduce disease progression by up to 41% relative to placebo over 52 weeks.
The MuSyCA scale, recently developed by an NIH-funded consortium, combines key elements of patient-reported activities of daily living and motor examination to improve sensitivity in detecting progression in MSA clinical trials. Placebo patients worsened by approximately +9.7 points on MuSyCA over a year, while ATH434-treated groups showed treatment effects ranging from −1.9 points (75 mg dose) to −4.0 points (50 mg dose, p=0.034), underscoring the scale’s utility.
Consistent Efficacy Signals Across Measures
The findings align with prior results using the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, where ATH434 slowed disease progression by 35% to 53% relative to placebo depending on dose. This dual confirmation across different clinical instruments bolsters confidence in ATH434’s disease-modifying profile.
Alterity’s CEO Dr David Stamler emphasised the significance of MuSyCA as a new framework integrating patient function with neurological assessment, with plans to incorporate biomarkers such as neurofilament light chain and imaging to enhance trial sensitivity. This approach could set a new standard for evaluating therapies in MSA, a rare and devastating neurodegenerative disorder with no approved disease-modifying treatments.
ATH434’s Path to Phase 3 and Market Potential
ATH434 is an oral iron chaperone designed to reduce iron accumulation and abnormal protein aggregation, mechanisms implicated in MSA and related Parkinsonian disorders. It has previously demonstrated target engagement and a favourable safety profile. The drug has received Fast Track and Orphan Drug designations from the FDA and European Commission, signalling regulatory recognition of its potential.
This latest analysis supports Alterity’s ongoing preparations for a pivotal Phase 3 trial, following encouraging regulatory feedback earlier this year. Notably, the company has been advancing its Phase 3 program with positive FDA input on clinical and non-clinical development aspects, as well as manufacturing controls and trial design, positioning it well for the next development phase.
Given the rarity and rapid progression of MSA, ATH434’s ability to slow functional decline could represent a meaningful breakthrough for patients currently facing no cure and limited treatment options.
Bottom Line?
ATH434’s Phase 2 data using MuSyCA offer a promising signal for disease modification in MSA, setting a critical foundation for upcoming Phase 3 trials.
Questions in the middle?
- How will regulators respond to the novel MuSyCA scale in pivotal trial design?
- Can ATH434’s efficacy signals translate into clinically meaningful benefits in a larger Phase 3 cohort?
- What role will biomarkers like neurofilament light chain play in confirming ATH434’s mechanism?
